Alzheimer’s Disease Pharmacotherapy in Relation to Cholinergic System Involvement

• Main Authors: Gabriela Dumitrita Stanciu, Andrei Luca, Razvan Nicolae Rusu, Veronica Bild, Sorin Ioan Beschea Chiriac, Carmen Solcan, Walther Bild, Daniela Carmen Ababei
• Format: Article
• Language: English
• Published: MDPI AG 2019-12-01
• Series: Biomolecules
• Subjects: alzheimer’s disease; cholinergic system; cholinesterase inhibitors; acetylcholinesterase; butyrylcholinesterase
• Online Access: https://www.mdpi.com/2218-273X/10/1/40

Alzheimer’s disease, a major and increasing global health challenge, is an irreversible, progressive form of dementia, associated with an ongoing decline of brain functioning. The etiology of this disease is not completely understood, and no safe and effective anti-Alzheimer’s disease drug to prevent, stop, or reverse its evolution is currently available. Current pharmacotherapy concentrated on drugs that aimed to improve the cerebral acetylcholine levels by facilitating cholinergic neurotransmission through inhibiting cholinesterase. These compounds, recognized as cholinesterase inhibitors, offer a viable target across key sign domains of Alzheimer’s disease, but have a modest influence on improving the progression of this condition. In this paper, we sought to highlight the current understanding of the cholinergic system involvement in Alzheimer’s disease progression in relation to the recent status of the available cholinesterase inhibitors as effective therapeutics.